Franklyn J A, Maisonneuve P, Sheppard M C, Betteridge J, Boyle P
Department of Medicine, University of Birmingham, United Kingdom.
N Engl J Med. 1998 Mar 12;338(11):712-8. doi: 10.1056/NEJM199803123381103.
Hyperthyroidism affects many organ systems, but the effects are usually considered reversible. The long-term effects of hyperthyroidism on mortality are not known.
We conducted a population-based study of mortality in a cohort of 7209 subjects with hyperthyroidism who were treated with radioactive iodine in Birmingham, United Kingdom, between 1950 and 1989. The vital status of the subjects was determined on March 1, 1996, and causes of death were ascertained for those who had died. The data on the causes of death were compared with data on age-specific mortality in England and Wales. The standardized mortality ratio was used as a measure of relative risk, and the effect of covariates on mortality was assessed by regression analysis.
During 105,028 person-years of follow-up, 3611 subjects died; the expected number of deaths was 3186 (standardized mortality ratio, 1.1; 95 percent confidence interval, 1.1 to 1.2; P<0.001). The risk was increased for deaths due to thyroid disease (106 excess deaths; standardized mortality ratio, 24.8; 95 percent confidence interval, 20.4 to 29.9), cardiovascular disease (240 excess deaths; standardized mortality ratio, 1.2; 95 percent confidence interval, 1.2 to 1.3), and cerebrovascular disease (159 excess deaths; standardized mortality ratio, 1.4; 95 percent confidence interval, 1.2 to 1.5), as well as fracture of the femur (26 excess deaths; standardized mortality ratio, 2.9; 95 percent confidence interval, 2.0 to 3.9). The excess mortality was most evident in the first year after radioiodine therapy and declined thereafter.
Among patients with hyperthyroidism treated with radioiodine, mortality from all causes and mortality due to cardiovascular and cerebrovascular disease and fracture are increased.
甲状腺功能亢进影响多个器官系统,但通常认为这些影响是可逆的。甲状腺功能亢进对死亡率的长期影响尚不清楚。
我们对1950年至1989年间在英国伯明翰接受放射性碘治疗的7209例甲状腺功能亢进患者进行了一项基于人群的死亡率研究。于1996年3月1日确定了这些患者的生命状态,并查明了死亡患者的死因。将死因数据与英格兰和威尔士的年龄特异性死亡率数据进行比较。标准化死亡率比值用作相对风险的衡量指标,并通过回归分析评估协变量对死亡率的影响。
在105,028人年的随访期间,3611例患者死亡;预期死亡人数为3186例(标准化死亡率比值为1.1;95%置信区间为1.1至1.2;P<0.001)。甲状腺疾病导致的死亡风险增加(额外死亡106例;标准化死亡率比值为24.8;95%置信区间为20.4至29.9),心血管疾病(额外死亡240例;标准化死亡率比值为1.2;95%置信区间为1.2至1.3)、脑血管疾病(额外死亡159例;标准化死亡率比值为1.4;95%置信区间为1.2至1.5)以及股骨骨折(额外死亡26例;标准化死亡率比值为2.9;95%置信区间为2.0至3.9)。额外死亡率在放射性碘治疗后的第一年最为明显,此后下降。
在接受放射性碘治疗的甲状腺功能亢进患者中,各种原因导致的死亡率以及心血管疾病、脑血管疾病和骨折导致的死亡率均有所增加。